Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GKB OphthalmicsNSE:GKB 44 EV-to-EBIT is 5.17 as of Aug. 25, 2026. GuruFocus rates NSE:GKB with a GF Score™ of 44/100 and a GF Value™ of ₹126.23 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 476 Medical Devices & Instruments companies, GKB Ophthalmics ranks better than 83.61% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
GKB Ophthalmics's Enterprise Value for the quarter that ended in Jun. 2026 was ₹446 Mil.
GKB Ophthalmics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKB Ophthalmics EV-to-EBIT Related Terms
GKB Ophthalmics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for GKB Ophthalmics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, GKB Ophthalmics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GKB Ophthalmics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GKB Ophthalmics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where GKB Ophthalmics's EV-to-EBIT falls into.
GKB Ophthalmics's current Enterprise Value is ₹420 Mil.
GKB Ophthalmics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKB Ophthalmics (NSE:GKB) has a EV-to-EBIT of 5.17 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GKB Ophthalmics and its competitors. According to the industry distribution chart, GKB Ophthalmics ranks #78 out of 476 companies in the Medical Devices & Instruments industry, placing it in the top 16.4%.
Is GKB Ophthalmics' EV-to-EBIT too high?
GKB Ophthalmics' current EV-to-EBIT is 5.17. The Medical Devices & Instruments industry median EV-to-EBIT is 19.00. GKB Ophthalmics' value of 5.17 is 72.8% below this industry median. Based on the distribution chart, GKB Ophthalmics ranks #78 out of 476 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, GKB Ophthalmics ranks #78 out of 476 companies for EV-to-EBIT. This places GKB Ophthalmics in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.00. GKB Ophthalmics' value of 5.17 is 72.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.00, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GKB Ophthalmics's current EV-to-EBIT of 5.17 is 72.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GKB Ophthalmics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GKB Ophthalmics's current EV-to-EBIT is 5.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.23, compared to a current price of ₹63.00 — trading 50.1% below its estimated fair value. The current EV-to-EBIT is 5.17 and 72.8% below the Medical Devices & Instruments industry median of 19.00. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current EV-to-EBIT is 5.17 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?
Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued.
The current stock price of ₹63.00 is trading 50.1% below its estimated GF Value™ of ₹126.23.
GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.
Key valuation signals for NSE:GKB:
EV-to-EBIT: 5.17
GF Value™: ₹126.23 vs. price of ₹63.00 (50.1% below fair value)
Industry Position: 72.8% below the Medical Devices & Instruments median (#78 of 476)
No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score
Get the complete analysis for NSE:GKB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKB has been successfully added to your 
